408
Participants
Start Date
September 5, 2013
Primary Completion Date
December 11, 2018
Study Completion Date
December 11, 2018
Lamivudine/zidovudine
"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
Efavirenz
Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
Raltegravir
Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
Bhumibol Adulyadej Hospital, Bangkok
Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok
Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro
South Flordia Childrens Diagnostic & Treatment Center, Fort Lauderdale
St Jude's Children's Research Hospital, Memphis
Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai
Tulane University, New Orleans
University of Washington Medical Center, Seattle
Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires
Fundacion Huesped - Hospital Juan A Fernandez, Buenos Aires
Perinatal HIV Research Unit-Chris Hani Baragwanath Hospital, Soweto
Kilimanjaro Christian Medical Centre (KCMC), Moshi
SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte
Univ. Caxias do Sul Brazil NICHD CRS, Caxias do Sul
Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre
Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro
Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro
Univ. of Sao Paulo Brazil NICHD CRS, São Paulo
San Juan City Hosp. PR NICHD CRS, San Juan
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Westat
OTHER